Biotech Values

[DewDiligence]

Your take is on-target, IMO. Market cap* should be used as a reality check rather than a substitute for genuine DD. That’s why I suggested that #msg-73956933 should be required reading for PPHM longs, who have been proclaiming for about a decade that clinical greatness is just around the corner despite the stock’s minuscule enterprise value and the lack of interest from any partner or suitor.

*Enterprise value is a better metric than market cap for this purpose.